Effectiveness and Safety of PD-1 Inhibitors’ Treatment for Patients with Non-Small-Cell Lung Cancer in China: A Real-World Study

Table 1

Baseline characteristics of 167 patients.

Variables	n (%)
Ages (years)
Median age	61.5 (35–83)
≥65	66 (39.52)
Sex
Male	129 (77.25)
Female	38 (22.75)
Smoking history
Never-smoker	98 (58.68)
Current or ex-smoker	69 (41.32)
Histology
Nonsquamous	111 (66.47)
Squamous	56 (33.53)
Genetic mutation
EGFR	22 (13.17)
ALK	3 (1.80)
KARS	11 (6.59)
Other	16 (9.58)
None	54 (32.34)
Unknown	61 (36.53)
Pathological staging
III	38 (20.75)
IV	129 (77.25)
Therapy lines
First-line	107 (64.07)
Posterior-line	60 (35.93)
Presence of treating with antibiotic during immunotherapy
Yes	54 (32.34)
No	113 (67.66)
Types of PD-1 inhibitors used
Camrelizumab	48 (28.74)
Sintilimab	72 (43.11)
Toripalimab	29 (17.37)
Camrelizumab, sintilimab	5 (2.99)
Camrelizumab, toripalimab	8 (4.79)
Sintilimab, toripalimab	4 (2.40)
Camrelizumab, sintilimab, and toripalimab	1 (0.60)